Preclincial evaluation of Gold-DTDTPA Nanoparticles As Theranostic Agents In Prostate Cancer Radiotherapy

Karl T Butterworth, James R Nicol, Mihaela Ghita, Soraia Rosa, Pankaj Chaudhary, Conor K McGarry, Helen O McCarthy, Gloria Jimenez-Sanchez, Rana Bazzi, Stéphane Roux, Olivier Tillement, Jonathan A Coulter, Kevin M Prise

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)
463 Downloads (Pure)


AIM: Gold nanoparticles have attracted significant interest in cancer diagnosis and treatment. Herein, we evaluated the theranostic potential of dithiolated diethylenetriamine pentaacetic acid (DTDTPA) conjugated AuNPs (Au@DTDTPA) for CT-contrast enhancement and radiosensitization in prostate cancer.

MATERIALS & METHODS: In vitro assays determined Au@DTDTPA uptake, cytotoxicity, radiosensitizing potential and DNA damage profiles. Human PC3 xenograft tumor models were used to determine CT enhancement and radiation modulating effects in vivo.

RESULTS: Cells exposed to nanoparticles and radiation observed significant additional reduction in survival compared with radiation only. Au@DTDTPA produced a CT enhancement of 10% and a significant extension in tumor growth delay from 16.9 days to 38.3 compared with radiation only.

CONCLUSION: This study demonstrates the potential of Au@DTDTPA to enhance CT-image contrast and simultaneously increases the radiosensitivity of prostate tumors.

Original languageEnglish
Pages (from-to)2035-47
Number of pages13
Issue number16
Early online date27 Jul 2016
Publication statusPublished - Aug 2016


Dive into the research topics of 'Preclincial evaluation of Gold-DTDTPA Nanoparticles As Theranostic Agents In Prostate Cancer Radiotherapy'. Together they form a unique fingerprint.

Cite this